Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.
Breast Cancer Res Treat. 2016 Jun 8. [Epub ahead of print]
Kommentar schreiben
Di
11
Okt
2022
Sailing Croatia 2022
Fr
18
Jun
2021
Sailing trip Italy Greece
16
Apr
Sa
24
2020
01
Sep
7 weeks sailing in Croatia
23
Mai
Thanks to Saskia and Patrick for these recordings
Kommentar schreiben